Atopic dermatitis (AD) is a chronic inflammatory skin condition with a significant impact on quality of life. Emerging targeted therapies, including oral Janus kinase (JAK) inhibitors and biologics such as dupilumab, have revolutionized its management. This article compares the efficacy and safety profiles of two oral JAK inhibitors, upadacitinib and abrocitinib, against the well-established interleukin-4 receptor antagonist dupilumab. Clinical trial data and post-marketing reports are analyzed to provide insights into their clinical applications.
Introduction
AD is characterized by pruritus, skin barrier dysfunction, and immune dysregulation, primarily involving Th2 cytokines. Dupilumab, an anti-IL-4/IL-13 receptor monoclonal antibody, was the first biologic approved for moderate-to-severe AD, demonstrating significant efficacy and a favorable safety profile. Subsequently, oral JAK inhibitors, including upadacitinib and abrocitinib, have emerged as alternatives, offering rapid onset of action and convenience. This review evaluates these therapies based on efficacy, safety, and patient considerations.
Methods
Data were gathered from phase III clinical trials, systematic reviews, and real-world evidence focusing on treatment outcomes for moderate-to-severe AD. Key endpoints included Eczema Area and Severity Index (EASI)-75, EASI-90, and safety metrics such as adverse event (AE) profiles.
Efficacy
Dupilumab
Dupilumab has demonstrated robust efficacy in pivotal trials (SOLO 1, SOLO 2), achieving EASI-75 in 50-60% of patients after 16 weeks. Its efficacy is consistent across diverse populations, including pediatric and elderly patients. Sustained improvement in pruritus and sleep quality is a hallmark of dupilumab therapy.
Upadacitinib
Upadacitinib, a selective JAK1 inhibitor, has shown superior efficacy in achieving EASI-75 and EASI-90 compared to placebo and dupilumab in head-to-head trials (e.g., Measure Up and Heads Up studies). Notably, it provides rapid relief, with significant improvements observed as early as week 2. Upadacitinib’s efficacy is consistent across different age groups and disease severities.
Abrocitinib
Abrocitinib, another selective JAK1 inhibitor, also demonstrates rapid and substantial improvement in AD severity. In JADE COMPARE, abrocitinib outperformed dupilumab in reducing pruritus early in the treatment course. EASI-75 response rates are comparable to those of upadacitinib, although slightly lower in some studies.
Safety
Dupilumab (Dupixent)
The safety profile of dupilumab is well-established, with conjunctivitis being the most common AE. Serious AEs are rare, and the lack of systemic immunosuppression makes it a preferred option for long-term use.
Upadacitinib (Rinvoq)
Upadacitinib is associated with a higher incidence of AEs, including acne, headache, and nasopharyngitis. Serious risks include thromboembolism, infections, and hepatic enzyme elevation. Its use requires regular monitoring, particularly in patients with cardiovascular risk factors.
Abrocitinib (Cibinqo)
Similar to upadacitinib, abrocitinib is linked to AEs such as nausea, headache, and acne. Thromboembolic events and infections, including herpes zoster, are notable concerns. Dose-dependent risks necessitate careful patient selection and monitoring.
Discussion
While dupilumab remains the cornerstone for AD treatment due to its established safety and efficacy, oral JAK inhibitors offer compelling advantages, including rapid symptom relief and oral administration. However, the safety concerns associated with JAK inhibitors, particularly regarding infections, acneiform eruption/acne, anemia, neutropenia, thrombocytopenia and hyperlipidemia, limit their use in certain populations. Recent studies have not shown any increased risks of malignancies, major adverse cardiovascular events, venous thromboembolism, renal events or serious GI events. Personalized treatment decisions should consider patient comorbidities, treatment goals, and preferences.
Conclusion
Upadacitinib and abrocitinib provide highly effective alternatives to dupilumab for moderate-to-severe AD, with faster onset of action but greater safety concerns. Dupilumab remains a safer long-term option for many patients. Ongoing studies and real-world data will further clarify the optimal use of these therapies in clinical practice.

